Download PDF
TumorDiagnostik & Therapie 2022; 43(02): 104-111
DOI: 10.1055/a-1688-7767
Übersicht
Schwerpunkt

Neue Entwicklungen in der Immuntherapie des Ösophagus- und Magenkarzinoms

Anica Högner
,
Peter Thuss-Patience
› Further Information
Also available at
    Permissions and Reprints

Die Immuncheckpoint-Inhibitoren etablieren sich als neuer Therapiestandard in der Behandlung von oberen gastrointestinalen Tumoren in jeder Therapielinie, und deren Implementierung in die aktuellen S3-Leitlinien wird erwartet. Dieser Artikel konzentriert sich auf die neuen Entwicklungen der Immuntherapie des Ösophagus- und Magenkarzinoms und diskutiert die aktuellen Zulassungen basierend auf den jeweiligen Studiendaten.

Publication History

Article published online:
02 March 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Referenzen

  • 1 Wilke H, Muro K, Van Cutsem E. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15 (11) 1224-1235
    CrossrefPubMedSearch in Google Scholar
  • 2 Shitara K, Doi T, Dvorkin M. et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018; 19 (11) 1437-1448
    CrossrefPubMedSearch in Google Scholar
  • 3 Moehler M, Ajani JA, Kuzdzal J. et al. 1381P Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577. Annals of Oncology 2021; 32: S1045-S1046
    CrossrefPubMedSearch in Google Scholar
  • 4 Sun J-M, Shen L, Shah MA. et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. The Lancet 2021; 398: 759-771
    CrossrefPubMedSearch in Google Scholar
  • 5 Kojima T, Shah MA, Muro K. et al. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin Oncol 2020; 38 (35) 4138-4148
    CrossrefPubMedSearch in Google Scholar
  • 6 Kato K, Cho BC, Takahashi M. et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20 (11) 1506-1517
    CrossrefPubMedSearch in Google Scholar
  • 7 Janjigian YY, Shitara K, Moehler M. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021; 398: 27-40
    CrossrefPubMedSearch in Google Scholar
  • 8 Janjigian YY, Kawazoe A, Yanez PE. et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study. JCO 2021; 39 (Suppl. 15) 4013
    CrossrefPubMedSearch in Google Scholar
  • 9 Kang Y-K, Boku N, Satoh T. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538–12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390: 2461-2471
    CrossrefPubMedSearch in Google Scholar
  • 10 Fuchs CS, Doi T, Jang RW-J. et al. KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. JCO 2017; 35 (Suppl. 15) 4003
    CrossrefPubMedSearch in Google Scholar
  • 11 Kelly RJ, Ajani JA, Kuzdzal J. et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med 2021; 384 (13) 1191-1203
    CrossrefPubMedSearch in Google Scholar
  • 12 Kelly RJ, Ajani JA, Kuzdzal J. et al. Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577. JCO 2021; 39 (Suppl. 15) 4003
    CrossrefPubMedSearch in Google Scholar
  • 13 Chau I, Doki Y, Ajani JA. et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study. JCO 2021; 39 (Suppl. 18) LBA4001
    CrossrefPubMedSearch in Google Scholar
  • 14 Xu R, Luo H, Lu J. et al. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC). JCO 2021; 39 (Suppl. 15) 4000
    CrossrefPubMedSearch in Google Scholar
  • 15 Xu J, Jiang H, Pan Y. et al. LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study. Annals of Oncology 2021; 32: S1331
    CrossrefPubMedSearch in Google Scholar
  • 16 Xu R-H, Wang F, Cui C. et al. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC). Annals of Oncology 2021; 32: S1041
    CrossrefPubMedSearch in Google Scholar
  • 17 Shen L, Kato K, Kim S-B. et al. RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma. JCO 2021; 39 (Suppl. 15) 4012-4012
    CrossrefPubMedSearch in Google Scholar
  • 18 Al-Batran S-E, Pauligk C, Hofheinz R. et al. Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK. JCO 2019; 37 (Suppl. 15) TPS4142
    CrossrefPubMedSearch in Google Scholar
  • 19 Al-Batran S-E, Lorenzen S, Thuss-Patience PC. et al. 1494P Updated safety data of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma – A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK. Annals of Oncology 2020; 31: S927-S928
    CrossrefPubMedSearch in Google Scholar
  • 20 Al-Batran S-E, Homann N, Pauligk C. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393: 1948-1957
    CrossrefPubMedSearch in Google Scholar
  • 21 Bang Y-J, Van Cutsem E, Fuchs CS. et al. KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncol 2019; 15 (09) 943-952
    CrossrefPubMedSearch in Google Scholar
  • 22 Shitara K, Van Cutsem E, Bang Y-J. et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol 2020; 6 (10) 1571-1580
    CrossrefPubMedSearch in Google Scholar
  • 23 Moehler MH, Dvorkin M, Ozguroglu M. et al. Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC). JCO 2020; 38 (Suppl. 04) 278
    CrossrefPubMedSearch in Google Scholar
  • 24 Xu J, Jiang H, Pan Y. et al. LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study. Annals of Oncology 2021; 32: S1331
    CrossrefPubMedSearch in Google Scholar
  • 25 Shitara K, Özgüroğlu M, Bang Y-J. et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018; 392: 123-133
    CrossrefPubMedSearch in Google Scholar
  • 26 Shitara K, Özgüroğlu M, Bang Y-J. et al. The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061. JCO 2020; 38 (Suppl. 15) 4537
    CrossrefPubMedSearch in Google Scholar
  • 27 Högner A, Breithaupt K, Stein A. et al. RAP: A phase II trial with ramucirumab, avelumab, and paclitaxel as second line treatment in gastro-esophageal adenocarcinoma of the arbeitsgemeinschaft internistische onkologie (AIO). JCO 2019; 37 (Suppl. 15) TPS4148
    CrossrefPubMedSearch in Google Scholar